French Clarify Use Of Plaquenil & Kaletra In COVID-19
Products Can Be Used In Hospitals And Clinical Trials
Executive Summary
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
You may also be interested in...
Indian Industry Gets HCQ, Paracetamol Exports Rolling
Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.
AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.